BIOHARVEST SCIENCES INC.

Early commercial-stage biotech growing revenue strongly but still deeply loss-making and burning cash, with an adequate but finite runway.

Strengths

• Revenue up 37% (68.2nd pct) and cash runway ~9.6 quarters (64th pct); current ratio 3.97
• Gross margin ~59% supports a path toward scale

Risks

• Operating margin -16%, net margin -32%, ROE -43.8%; negative FCF of ~$9.6M (FCF margin -27.8%)
• Cash-burn dependence on future financing as a newly public company with limited internal-control attestation

Notable findings

• RestatementRECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Since the beginning of the last completed financial year, the Company has not been required to prepare an accounting restatement that required recovery 8-K ↗
• Net lossNet loss (net margin -32.3%)
• Cash burnNegative free cash flow (-9.6M)
• Notable holderHeld by 1 notable fund(s): CITADEL ADVISORS LLC (as of 2026-03-31)